« Previous
Next »
Geriatric Nursing
Volume 27, Issue 1
, Pages 16-18
, January 2006
Management of Osteoporosis in Older Persons
References
-
.
Bone health and osteoporosis
(a report of the Surgeon General)
. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004;
Available at: http://www.surgeongeneral.gov/library/bonehealth/content.html. Cited July 8, 2005
- . The diagnosis of osteoporosis . J Bone Miner Res . 1994;9:1137–1141
-
.
British Geriatrics Society and the American Academy of Orthopaedic Surgeons Panel on Falls Prevention. Guideline for the prevention of falls in older persons
.
JAGS
. 2001;49:664–672
-
.
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis
(2001 edition, with selected updates for 2003)
.
Endocrine Prac
. 2003;9:544–564
-
Secondary causes of steoporosis
.
Mayo Clinic Proc
. 2002;77:453–468
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures . Lancet . 1996;348:1535–1541
- Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures (results from the Fracture Intervention Trial) . JAMA . 1998;280:2077–2082
- Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis (a randomized controlled trial) . JAMA . 1999;282:1344–1352
- Effect of risedronate on the risk of hip fracture in elderly women (Hip Intervention Program Study Group) . N Engl J Med . 2001;344:333–340
- A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis (the Prevent Recurrence of Osteoporotic Fractures study) . Am J Med . 2000;109:267–276
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women (principal results from the Women’s Health Initiative randomized controlled trial) . JAMA . 2002;288:321–333
- Effects of estrogen plus progestin on risk of fracture and bone mineral density (the Women’s Health Initiative randomized trial) . JAMA . 2003;290:1729–1738
- Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene (results from a 3-year, randomized, clinical trial) . JAMA . 1999;282:637–645
- Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis . N Engl J Med . 2001;344:1434–1441
- Prevention of nonvertebral fractures by alendronate. A meta-analysis . JAMA . 1997;277:1159–1164
-
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older
(implications for use of antiresorptive agents in the old and oldest old)
.
JAGS
. 2004;52:1832–1839
PII: S0197-4572(05)00463-5
doi: 10.1016/j.gerinurse.2005.12.001
© 2006 Mosby, Inc. All rights reserved.
« Previous
Next »
Geriatric Nursing
Volume 27, Issue 1
, Pages 16-18
, January 2006
